Patents by Inventor Stefan Miller
Stefan Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150165013Abstract: The present invention relates to a method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one Mycobacterium species with a composition having the activity of degrading the cell wall of a Mycobacterium species, the composition comprising: (a) a first fusion protein including (i) a first endolysin or a first domain, both having a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptideType: ApplicationFiled: July 1, 2013Publication date: June 18, 2015Inventor: Stefan Miller
-
Publication number: 20150140572Abstract: The present invention relates to a composition having the activity of degrading the cell wall of a Mycobacterium species comprising: (a) a first fusion protein including (i) a domain with a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, D-Ala-m-DAP (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase, (ii) at least one peptide stretch fused to the N- or C-terminus of the domain with the first enzymatic activity; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the first fusion protein; and (b) a second fusion protein including (i) a domain with a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hyType: ApplicationFiled: July 1, 2013Publication date: May 21, 2015Inventors: Stefan Miller, Robert Andreas Fischer
-
Publication number: 20150118731Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Rob LAVIGNE, Stefan MILLER, Yves BRIERS, Guido VOLCKAERT, Maarten WALMAGH
-
Publication number: 20150024469Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Yves BRIERS, Rob LAVIGNE, Maarten WALMAGH, Stefan MILLER
-
Patent number: 8932580Abstract: The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.Type: GrantFiled: July 28, 2009Date of Patent: January 13, 2015Assignees: Hyglos Invest GmbH, Biomerieux S.A.Inventors: Michael Schutz, Renate Grassl, Roman Meyer, Sibylle Frick, Ingrid Robl, Thomas Zander, Stefan Miller
-
Publication number: 20140377775Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.Type: ApplicationFiled: July 29, 2014Publication date: December 25, 2014Applicant: HYGLOS INVEST GMBHInventors: Stefan MILLER, Roman MEYER, Renate GRASSL, Manfred BIEBL, Holger GRALLERT
-
Patent number: 8906365Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: GrantFiled: June 28, 2010Date of Patent: December 9, 2014Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
-
Patent number: 8846865Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.Type: GrantFiled: August 24, 2010Date of Patent: September 30, 2014Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
-
Patent number: 8822641Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.Type: GrantFiled: November 21, 2012Date of Patent: September 2, 2014Assignee: Hyglos Invest GmbHInventors: Stefan Miller, Roman Meyer, Renate Grassl, Manfred Biebl, Holger Grallert
-
Publication number: 20140120074Abstract: The present invention relates to a fusion protein comprising an endolysin with an amino acid sequence according to SEQ ID NO: 1 and fragments and/or derivatives thereof and an additional cationic or polycationic peptide, an amphipatic peptide, a sushi peptide, a defensin, a hydrophobic peptide or an antimicrobial peptide fused to said endolysin, fragment and/or derivative at the N- and/or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of staphylococcal infections, as diagnostic means, as cosmetic substance or as sanitizing agent.Type: ApplicationFiled: April 27, 2012Publication date: May 1, 2014Applicant: LYSANDO AGInventor: Stefan Miller
-
Publication number: 20130344055Abstract: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive.Type: ApplicationFiled: December 23, 2011Publication date: December 26, 2013Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, LYSANDO AGInventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
-
Patent number: 8609348Abstract: Bacteriophage adhesion proteins binding to the O-antigen of gram negative bacteria, but lacking the ability of binding to a bacteriophage and of hydrolysing lipopolysaccharides, are described, as well as nucleic acid molecules encoding the proteins. In addition, methods for generating the bacteriophage adhesion proteins and their use in detection, purification and enrichment of bacteria are described.Type: GrantFiled: July 3, 2009Date of Patent: December 17, 2013Assignee: Biomerieux S.A.Inventors: Manfred Biebl, Renate Grassl, Monika Walter, Stefan Miller
-
Patent number: 8551719Abstract: The invention relates to a method for detecting endotoxins in a sample.Type: GrantFiled: February 20, 2013Date of Patent: October 8, 2013Assignee: Hyglos Invest GmbHInventors: Roman Meyer, Michael Schütz, Holger Grallert, Renate Grassl, Stefan Miller
-
Publication number: 20130244224Abstract: The invention relates to a method for detecting endotoxins in a sample.Type: ApplicationFiled: February 20, 2013Publication date: September 19, 2013Applicant: HYGLOS INVEST GMBHInventors: Roman MEYER, Michael SCHÜTZ, Holger GRALLERT, Renate GRASSL, Stefan MILLER
-
Patent number: 8438119Abstract: Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having foundation layer functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described.Type: GrantFiled: March 30, 2006Date of Patent: May 7, 2013Assignee: SAP AGInventors: Joachim Puteick, Martin Rogge, Hendrik Geipel, Andrea Pluemper, Andreas Huppert, Kai-Uwe Pielka, Ashwin Reddy Yeddula, Matthias Schmitt, Toralf Grossmann, Andreas Neumann, Bare Said, Stefan Miller, Michael Neumann, Florian Rehfeld, Ingo Bruss, Horst Schaude, Michael Bauer, Andreas Morsch, Silke Storch, Klaus Bahr, Bernd Schmitt, Michael Meyringer, Dirk Henrich
-
Patent number: 8394597Abstract: The invention relates to a method for detecting endotoxins in a sample.Type: GrantFiled: December 20, 2004Date of Patent: March 12, 2013Assignee: Hyglos Invest GmbHInventors: Roman Meyer, Michael Schütz, Holger Grallert, Renate Grassl, Stefan Miller
-
Publication number: 20130052182Abstract: The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Applicant: LYSANDO AGInventor: Stefan Miller
-
Patent number: 8329393Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.Type: GrantFiled: July 12, 2011Date of Patent: December 11, 2012Assignee: Hyglos Invest GmbHInventors: Stefan Miller, Roman Meyer, Renate Grassl, Manfred Biebl, Holger Grallert
-
Publication number: 20120195872Abstract: The present invention relates to antimicrobial agents against Gram-positive bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-positive bacteria and an additional peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-positive bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-positive bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: June 28, 2010Publication date: August 2, 2012Applicant: LYSANDO AGInventor: Stefan Miller
-
Publication number: 20120189606Abstract: The present invention relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: June 28, 2010Publication date: July 26, 2012Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh